Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 8
2004 8
2005 14
2006 14
2007 7
2008 8
2009 9
2010 9
2011 7
2012 7
2013 9
2014 7
2015 10
2016 15
2017 19
2018 14
2019 16
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

180 results
Results by year
Filters applied: . Clear all
Page 1
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Hofmann L, et al. Among authors: schuler g. Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13. Eur J Cancer. 2016. PMID: 27085692
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L. Moreira A, et al. Among authors: schuler g. Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17. Eur J Cancer. 2019. PMID: 30453170
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Zimmer L, et al. Among authors: schuler g. Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13. Eur J Cancer. 2016. PMID: 27084345
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
Moreira A, Leisgang W, Schuler G, Heinzerling L. Moreira A, et al. Among authors: schuler g. Immunotherapy. 2017 Jan;9(2):115-121. doi: 10.2217/imt-2016-0138. Immunotherapy. 2017. PMID: 28128709
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.
Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Fischer A, et al. Among authors: schuler g. Gut. 2016 Oct;65(10):1642-64. doi: 10.1136/gutjnl-2015-310022. Epub 2015 Jul 24. Gut. 2016. PMID: 26209553 Free PMC article.
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.
Wiesinger M, März J, Kummer M, Schuler G, Dörrie J, Schuler-Thurner B, Schaft N. Wiesinger M, et al. Among authors: schuler g. Cancers (Basel). 2019 Aug 16;11(8):1198. doi: 10.3390/cancers11081198. Cancers (Basel). 2019. PMID: 31426437 Free PMC article.
Personalized cancer immunotherapy using Systems Medicine approaches.
Gupta SK, Jaitly T, Schmitz U, Schuler G, Wolkenhauer O, Vera J. Gupta SK, et al. Among authors: schuler g. Brief Bioinform. 2016 May;17(3):453-67. doi: 10.1093/bib/bbv046. Epub 2015 Jul 14. Brief Bioinform. 2016. PMID: 26174229 Review.
Senescence markers: Predictive for response to checkpoint inhibitors.
Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L. Moreira A, et al. Among authors: schuler g. Int J Cancer. 2019 Mar 1;144(5):1147-1150. doi: 10.1002/ijc.31763. Epub 2018 Dec 4. Int J Cancer. 2019. PMID: 30151962 Free article.
NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells.
Bosch NC, Voll RE, Voskens CJ, Gross S, Seliger B, Schuler G, Schaft N, Dörrie J. Bosch NC, et al. Among authors: schuler g. Ther Adv Med Oncol. 2019 Dec 11;11:1758835919891622. doi: 10.1177/1758835919891622. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31853267 Free PMC article.
C-reactive protein as an early marker of immune-related adverse events.
Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. Abolhassani AR, et al. Among authors: schuler g. J Cancer Res Clin Oncol. 2019 Oct;145(10):2625-2631. doi: 10.1007/s00432-019-03002-1. Epub 2019 Sep 6. J Cancer Res Clin Oncol. 2019. PMID: 31492984
180 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback